vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and FORRESTER RESEARCH, INC. (FORR). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($191.2M vs $101.1M, roughly 1.9× FORRESTER RESEARCH, INC.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs -6.5%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 0.5%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Forrester Research, Inc. is a research and advisory firm working in research, consulting and events. Forrester’s clients include large global business, technology and consumer enterprises. The firm is headquartered in Cambridge, MA.
AXSM vs FORR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $101.1M |
| Net Profit | — | $-33.9M |
| Gross Margin | — | 56.7% |
| Operating Margin | -33.1% | -36.6% |
| Net Margin | — | -33.5% |
| Revenue YoY | 57.4% | -6.5% |
| Net Profit YoY | — | -7941.4% |
| EPS (diluted) | — | $-1.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | $101.1M | ||
| Q3 25 | $171.0M | $94.3M | ||
| Q2 25 | $150.0M | $111.7M | ||
| Q1 25 | $121.5M | $89.9M | ||
| Q4 24 | $118.8M | $108.0M | ||
| Q3 24 | $104.8M | $102.5M | ||
| Q2 24 | $87.2M | $121.8M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | $-33.9M | ||
| Q3 25 | $-47.2M | $-2.1M | ||
| Q2 25 | $-48.0M | $3.9M | ||
| Q1 25 | $-59.4M | $-87.3M | ||
| Q4 24 | $-74.9M | $432.0K | ||
| Q3 24 | $-64.6M | $-5.8M | ||
| Q2 24 | $-79.3M | $6.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 56.7% | ||
| Q3 25 | — | 60.0% | ||
| Q2 25 | — | 55.5% | ||
| Q1 25 | — | 55.9% | ||
| Q4 24 | — | 58.8% | ||
| Q3 24 | — | 60.5% | ||
| Q2 24 | — | 57.3% |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | -36.6% | ||
| Q3 25 | -27.0% | 4.7% | ||
| Q2 25 | -24.5% | 6.2% | ||
| Q1 25 | -46.9% | -97.5% | ||
| Q4 24 | -61.1% | -0.5% | ||
| Q3 24 | -59.8% | -0.7% | ||
| Q2 24 | -89.5% | 9.3% |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | -33.5% | ||
| Q3 25 | -27.6% | -2.3% | ||
| Q2 25 | -32.0% | 3.5% | ||
| Q1 25 | -48.9% | -97.1% | ||
| Q4 24 | -63.1% | 0.4% | ||
| Q3 24 | -61.7% | -5.7% | ||
| Q2 24 | -91.0% | 5.2% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | $-1.75 | ||
| Q3 25 | $-0.94 | $-0.11 | ||
| Q2 25 | $-0.97 | $0.20 | ||
| Q1 25 | $-1.22 | $-4.62 | ||
| Q4 24 | $-1.54 | $0.02 | ||
| Q3 24 | $-1.34 | $-0.30 | ||
| Q2 24 | $-1.67 | $0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $63.3M |
| Total DebtLower is stronger | $70.0M | — |
| Stockholders' EquityBook value | — | $126.5M |
| Total Assets | $713.6M | $404.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | $63.3M | ||
| Q3 25 | $325.3M | $65.1M | ||
| Q2 25 | $303.0M | $67.8M | ||
| Q1 25 | $300.9M | $75.6M | ||
| Q4 24 | $315.4M | $56.1M | ||
| Q3 24 | $327.3M | $62.8M | ||
| Q2 24 | $315.7M | $58.9M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | $126.5M | ||
| Q3 25 | $73.7M | $157.7M | ||
| Q2 25 | $73.1M | $159.5M | ||
| Q1 25 | $53.2M | $147.4M | ||
| Q4 24 | $57.0M | $229.5M | ||
| Q3 24 | $92.9M | $234.3M | ||
| Q2 24 | $102.9M | $237.1M |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | $404.0M | ||
| Q3 25 | $669.3M | $414.2M | ||
| Q2 25 | $639.8M | $436.0M | ||
| Q1 25 | $596.7M | $439.8M | ||
| Q4 24 | $568.5M | $503.9M | ||
| Q3 24 | $561.5M | $505.3M | ||
| Q2 24 | $548.2M | $524.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-3.2M |
| Free Cash FlowOCF − Capex | — | $-4.3M |
| FCF MarginFCF / Revenue | — | -4.2% |
| Capex IntensityCapex / Revenue | — | 1.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $18.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $-3.2M | ||
| Q3 25 | $1.0M | $1.2M | ||
| Q2 25 | $-32.4M | $-3.6M | ||
| Q1 25 | $-43.4M | $26.7M | ||
| Q4 24 | $-26.2M | $-1.8M | ||
| Q3 24 | $-18.6M | $264.0K | ||
| Q2 24 | $-30.1M | $-2.9M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $-4.3M | ||
| Q3 25 | $988.0K | $524.0K | ||
| Q2 25 | $-32.4M | $-4.2M | ||
| Q1 25 | $-43.7M | $26.1M | ||
| Q4 24 | $-26.2M | $-2.5M | ||
| Q3 24 | $-18.7M | $-223.0K | ||
| Q2 24 | $-30.2M | $-3.7M |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | -4.2% | ||
| Q3 25 | 0.6% | 0.6% | ||
| Q2 25 | -21.6% | -3.8% | ||
| Q1 25 | -36.0% | 29.0% | ||
| Q4 24 | -22.1% | -2.3% | ||
| Q3 24 | -17.9% | -0.2% | ||
| Q2 24 | -34.6% | -3.1% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 1.1% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.0% | 0.5% | ||
| Q1 25 | 0.3% | 0.7% | ||
| Q4 24 | 0.0% | 0.6% | ||
| Q3 24 | 0.1% | 0.5% | ||
| Q2 24 | 0.1% | 0.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.93× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -4.24× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -0.46× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
FORR
| Research Segment | $82.2M | 81% |
| Consulting Segment | $16.2M | 16% |
| Billable Expenses | $1.5M | 2% |
| Professional Services | $1.4M | 1% |
